Profound Medical Reports 104% Revenue Growth and Reduced Net Loss in Q1 2026

summarizeSummary

Profound Medical Corp. reported robust Q1 2026 financial results, with revenue more than doubling year-over-year and a significant reduction in net loss, driven by strong capital equipment sales and recurring revenue.

check_boxKey Events

• Revenue Surges 104% Year-over-Year

  Total revenue for the first quarter of 2026 reached $5.34 million, a 104% increase compared to $2.62 million in the same period last year. This growth was primarily fueled by a 249% increase in capital equipment sales to $2.86 million and a 37.4% rise in recurring non-capital revenue to $2.47 million.

• Net Loss Significantly Reduced by 34%

  The company reported a net loss of $7.05 million for Q1 2026, a substantial improvement from the $10.72 million net loss in Q1 2025. Basic and diluted loss per share improved by 47% to $0.19 from $0.36 in the prior year.

• Operating Expenses Decrease Amidst Growth

  Total operating expenses decreased by 9% to $11.85 million, down from $13.02 million in Q1 2025. This reduction was mainly due to a 20% decrease in selling, general, and administrative (SG&A) expenses, partially offset by a 9% increase in research and development (R&D) expenses.

• Strong Liquidity Position

  Profound Medical Corp. ended the quarter with $50.30 million in cash and expects this, combined with product sales, to fund operating expenses and capital expenditures for at least the next 12 months. The company remains in compliance with its CIBC Credit Agreement financial covenants.

auto_awesomeAnalysis

Profound Medical Corp.'s first-quarter 2026 results demonstrate significant operational improvement and strong commercial traction for its TULSA-PRO system. The substantial revenue growth, coupled with a notable reduction in net loss and improved operating efficiency, indicates positive momentum in the company's commercialization efforts. The company's liquidity position, with sufficient cash to fund operations for at least the next 12 months, provides a stable outlook for continued growth and development. Investors should monitor sustained revenue growth and further improvements in profitability as the company continues its commercial expansion.